EPHA1 and neoplasm: Their probable clinical applicability can be categorized as follows: (a) tumor reductive agents which interact with various components of EPH/ephrin signaling; (b) carriers that target the EPH/ephrin system to deliver cytotoxic agents to tumor cells; (c) enhancers of the efficacy of other biologics or chemotherapeutics; and (d) anti-metastatic agents.